ALKS Alkermes Corp Total Debt to Capital

The price action of Alkermes plc (ALKS) is supported by the ideal condition of its own bio-plants equipped with certified machinery. The individual debt-to-equity ratio stands at 0.83. The business scales through patent protection of neurological agents, where high R&D expenditures transition into monopoly profits. Revenue is generated via US insurance payouts for complex injections for individuals with bipolar disorder and addictions.

Professional managers utilize fundamental filters to assess the financial stability and default risks of assets. This indicator, equal to 0.83, measures the proportion of borrowed funds to equity, which is critical for Alkermes plc (ALKS), as it shares clinical trial costs with partners; the historical debt-to-equity ratio clearly demonstrates the balance between the company's leverage and its financial independence.